The Impact of China's Human Genetic Resources Regime on Biopharma MNCs

May 14, 2021
| By Vincent Chow
China’s HGR regime has been significantly bolstered in the last two years, delaying the research and development activities of biopharma MNCs in the country

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
 

This premium content is reserved for
China Law & Practice Subscribers.

A Premium Subscription Provides:

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment

Subscribe Now

For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected].